Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

3
Delayed Quote. Delayed London Stock Exchange - 05/22 11:35:04 am
67.75 GBp   +3.04%
05/06 VERNALIS : Block Listing Six Monthly Review
05/06 VERNALIS : Non-Executive Director Buys Shares (DIRECTOR DEALINGS)
05/06 VERNALIS : Director/PDMR Shareholding
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
69.5(c) 68(c) 66.75(c) 65.75(c) 67.75(c) Last
1 540 971 206 084 103 171 246 466 184 680 Volume
+2.21% -2.16% -1.84% -1.50% +3.04% Change
More quotes
Financials ( GBP)
Sales 2015 18,3 M
EBIT 2015 -15,8 M
Net income 2015 -11,4 M
Finance 2015 11,7 M
Yield 2015 -
Sales 2016 -
EBIT 2016 -
Net income 2016 -
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016 -
Capi. / Sales 2015 15,8x
Capi. / Sales 2016 -
Capitalization 300 M
More Financials
Company
Vernalis Plc is a research and development stage pharmaceutical company.The company provides pharmaceutical products for a range of medical disorders.It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.The group has one marketed product,... 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
05/06 VERNALIS : and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR co..
05/06 VERNALIS : Block Listing Six Monthly Review
05/06 VERNALIS : Non-Executive Director Buys Shares (DIRECTOR DEALINGS)
05/06 VERNALIS : Director/PDMR Shareholding
05/04 VERNALIS : and Tris Pharma receive FDA approval of NDA for Tuzistra XR (codeine ..
05/01 VERNALIS : Says US Regulator Approves New Drug Application For Tuzistra
05/01 VERNALIS : and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (c..
05/01 VERNALIS : FDA approves NDA for Tuzistra XR
More news
Sector news : Biotechnology & Medical Research - NEC
05/22 SYNAGEVA BIOPHARMA : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investiga..
05/22 BLUEBIRD BIO : Announces Participation at the Jefferies 2015 Global Healthcare C..
05/21 ABBVIE : specifies breakdown of $21 billion Pharmacyclics deal
More sector news : Biotechnology & Medical Research - NEC


Comments 
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions